Nuclear transport modulators and uses thereof
Inventors
Sandanayaka, Vincent P. • Shechter, Sharon • Shacham, Sharon • McCauley, Dilara • Baloglu, Erkan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
Core Innovation
The invention provides an orally acceptable dosage form comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and a pharmaceutically acceptable carrier. The claim defines the compound through specified alternatives for R1, R2, R3, and R4, including nitrogen-containing heterocyclyl and heteroaryl substituents, wherein the compounds act as nuclear transport and CRM1 inhibitors. The provided patent content does not explicitly describe the problem addressed in the background section.
The document reports that Formula I compounds provide increased systemic exposure (AUC) combined with relatively low brain-to-plasma ratios and reduced brain penetration relative to other nuclear transport inhibitors. Preclinical evaluations of Compounds 1 and 2 demonstrate biological activity across tumor, arthritis, ear-inflammation, wound, obesity, and cerebral ischemia assays. Reported observations include reductions in xenograft tumor growth, paw swelling, clinical arthritis scores, ear inflammation, food intake, and body-weight gain.
Claims Coverage
The claims identify one independent claim directed to an orally acceptable dosage form, characterized by three inventive features.
Orally acceptable dosage form
The claim covers an orally acceptable dosage form comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
Defined Formula I compound
The compound is defined by specified substituent alternatives for R1, R2, R3, and R4, wherein R1 is hydrogen or C1–C4 alkyl, R2 is O or S, and R3 comprises designated nitrogen-containing heterocyclyl or heteroaryl options.
Pharmaceutically acceptable carrier
The dosage form further comprises a pharmaceutically acceptable carrier.
The independent claim centers on an orally acceptable dosage form containing the defined Formula I compound and a pharmaceutically acceptable carrier, supported by dependent limitations covering specific compound forms, dosage-form types, release profiles, blood-brain-barrier characteristics, and oral treatment methods for CRM1-mediated disorders.
Stated Advantages
Formula I compounds are reported to provide increased systemic exposure (AUC) and relatively low brain-to-plasma ratios, with reduced brain penetration relative to other nuclear transport inhibitors.
The document reports CRM1 inhibition and oral antitumor activity, including reduced Z-138 and A549 xenograft tumor growth in mice treated with Compound 2 compared with vehicle, as well as synergistic effects for combinations with doxorubicin or bortezomib.
The document reports reductions in arthritis scores, paw and joint swelling, clinical scores, arthritis histopathology, and ear inflammation in animal models.
Compound 2 treatment is associated with reduced food intake and body-weight gain or loss relative to controls in Zucker rats and high-fat-diet rats.
The document reports reduced disease manifestations in traumatic brain injury, cerebral ischemia, and wound-healing models.
Documented Applications
Oral treatment of CRM1-mediated disorders, including proliferative, angiogenesis, inflammatory, autoimmune, viral, wound, ophthalmological, neurodegenerative, abnormal-tissue-growth, food-intake, allergic, stroke, traumatic-brain-injury, and respiratory disorders.
Treatment of specific disorders including lupus, multiple sclerosis, muscular dystrophy, and amyotrophic lateral sclerosis.
Preclinical antitumor applications in Z-138 and A549 xenograft tumor models, radiosensitization, and combinations with doxorubicin, bortezomib, or radiation therapy.
Preclinical anti-inflammatory and autoimmune applications in arthritis, PMA-induced ear-inflammation, IMQ-induced disease, and cerebral ischemia/CCI-related models.
Food-intake and body-weight-related applications in diet-induced obesity studies, including Zucker rats and high-fat-diet rats.
Therapeutic uses in wound treatment and scar reduction using topical or oral Compound 1.
Interested in licensing this patent?